Brian McVeigh Net Worth

Brian McVeigh biography

Brian P. McVeigh is the Chief Business Officer of the company. He has served as Vice President of World Wide Business Development (“WWBD”), Transactions and Investment Management of GlaxoSmithKline plc in Pharmaceuticals Research and Development from October 2011 until November 2017. From November 2008 to October 2011, Mr. McVeigh was Vice President in a variety of positions including WWBD Transactions, Commercial Alliances and Mergers and Acquisitions (“M&A”), and Deal Finance and M&A. Prior to those roles, Mr. McVeigh was the Director of M&A Strategy and Transactions, and Business Development Transactions and Ventures from September 2006 to November 2008 and from September 2004 to September 2006, respectively. From May 1992 through September 2004, McVeigh was promoted through a variety of roles of increasing responsibility at GlaxoSmithKline plc. Most recently, Mr. McVeigh was the Chief Executive Officer and on the Board of Directors of KBP Biosciences from December 2017 until April 2018.

What is the salary of Brian McVeigh?

As the Chief Business Officer of Zafgen, the total compensation of Brian McVeigh at Zafgen is $1,462,930. There are no executives at Zafgen getting paid more.

How old is Brian McVeigh?

Brian McVeigh is 46, he's been the Chief Business Officer of Zafgen since 2018. There are 8 older and no younger executives at Zafgen. The oldest executive at Zafgen, Inc. is Thomas Daniel, 66, who is the Independent Director.

What's Brian McVeigh's mailing address?

Brian's mailing address filed with the SEC is 175 Portland St #4, Boston, MA 02114, USA.

Insiders trading at Zafgen

Over the last 10 years, insiders at Zafgen have traded over $14,218,922 worth of Zafgen stock and bought 689,531 units worth $3,998,442 . The most active insiders traders include James E Deerfield Mgmt L.P...., Bruce Booth, and Kevin P Starr. On average, Zafgen executives and independent directors trade stock every 53 days with the average trade being worth of $87,516. The most recent stock trade was executed by Thomas E. Hughes on 28 June 2018, trading 32,000 units of ZFGN stock currently worth $320,000.

What does Zafgen do?

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Zafgen executives and stock owners

Zafgen executives and other stock owners filed with the SEC include:

• Brian McVeigh,
  Chief Business Officer
• Frank Thomas,
  Independent Director
• Thomas Daniel,
  Independent Director
• Jonathan Leff,
  Director
• Thomas Hamilton,
  Director
• Priya Singhal,
  Head of Research and Development
• Michael Celano,
  Chief Financial Officer
• Carole Ben-Maimon,
  President, Chief Executive Officer, Director
• Joseph Truitt,
  Chairman of the Board
• Patrick Loustau,
  President
• Cameron Geoffrey Mc Donough,
  Director
• Frances K Heller,
  Director
• Robert J Perez,
  Director
• John L Lamattina,
  Director
• Dennis D Kim,
  Chief Medical Officer
• Alicia Secor,
  Chief Commercial Officer
• James E Deerfield Mgmt L.P....,
  
• Bruce Booth,
  Director
• Patricia L Allen,
  Chief Financial Officer
• James E Deerfield Mgmt L.P....,
  
• Jeffrey S. Hatfield,
  Chief Executive Officer
• Wendy Everett,
  Director
• Venture Fund Vii L P Atlas ...,
  
• Peter Barrett,
  Director
• Avi Y. Goldberg,
  Director
• Rock Ventures Lp Third Rock...,
  
• Rock Ventures Lp Third Rock...,
  
• Thomas E. Hughes,
  Chief Executive Officer
• Kevin P Starr,
  Director